Quantifying exploratory low dose compounds in humans with AMS

Advanced Drug Delivery Reviews

Volumn 63, Issue 7, 2011, Pages 518-531

  Dueker, Stephen R ^a   Vuong, Le T ^a   Lohstroh, Peter N ^a   Giacomo, Jason A ^a   Vogel, John S ^a  

^a Vitalea Science   (United States)

Author keywords

Absolute bioavailability; Accelerator mass spectrometry (AMS); Mass balance; Metabolism; Microdose; Microdosing; Microtracer; Microtracing; MIST; Nutrition; Physiochemistry

Indexed keywords

ABSOLUTE BIOAVAILABILITY; ACCELERATOR MASS SPECTROMETRY; MASS BALANCE; MICRODOSE; MICRODOSING; MICROTRACER; MICROTRACING; MIST; PHYSIOCHEMISTRY;

BIOCHEMISTRY; BIOLOGICAL MATERIALS; KNOWLEDGE BASED SYSTEMS; METABOLISM; PARTICLE ACCELERATORS; RESEARCH;

MASS SPECTROMETRY;

4 AMINOBUTYRIC ACID; BETA CAROTENE; BIOLOGICAL MARKER; BUPRANOLOL; CARBON 14; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CLOSANTEL; FEXOFENADINE; LEVODOPA; MELPHALAN; NELFINAVIR; NICLOSAMIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OXALIPLATIN; PLANT MEDICINAL PRODUCT; PLATINUM COMPLEX; POLYPEPTIDE ANTIBIOTIC AGENT; PRODRUG; RETINOL; RETINOL ESTER; WARFARIN;

ACCELERATOR MASS SPECTROMETRY; ANALYTIC METHOD; AREA UNDER THE CURVE; BIOCHEMISTRY; BIOMEDICINE; BIOTECHNOLOGY; BLADDER CANCER; CLINICAL STUDY; DIAGNOSTIC TEST; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG INTERACTION; DRUG METABOLISM; DRUG MICRODOSE; DRUG RESEARCH; DRUG TARGETING; ENVIRONMENTAL FACTOR; EXPLORATORY RESEARCH; HUMAN; ISOTOPE LABELING; LIPOPHILICITY; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MASS SPECTROMETRY; NONHUMAN; NUTRITIONAL SCIENCE; PHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION EXPOSURE; RESEARCH SUBJECT; REVIEW; SKIN ABSORPTION; TARGET CELL; VITAMIN SUPPLEMENTATION;

ANIMALS; CARBON RADIOISOTOPES; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS;

EID: 79957757042     PISSN: 0169409X     EISSN: 0169409X     Source Type: Journal    
DOI: 10.1016/j.addr.2010.10.009     Document Type: Review

References (99)

1. Vogel J., Turteltaub K., Finkel R., Nelson D. Accelerator mass spectrometry. Anal. Chem. 1995, 67:353A-359A.
2. Kutschera W. Progress in isotope analysis at ultra-trace level by AMS. Int. J. Mass Spectrom. 2005, 242:145-160.
3. Turteltaub K.W., Vogel J.S. Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research. Curr. Pharm. Des. 2000, 6:991-1007.
4. Turteltaub K.W., Frantz C.E., Creek M.R., Vogel J.S., Shen N., Fultz E. DNA adducts in model systems and humans. J. Cell. Biochem. Suppl. 1993, 17F:138-148.
5. Turteltaub K.W., Felton J.S., Gledhill B.L., Vogel J.S., Southon J.R., Caffee M.W., Finkel R.C., Nelson D.E., Proctor I.D., Davis J.C. Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proc. Natl Acad. Sci. USA 1990, 87:5288-5292.
6. Turteltaub K.W., Dingley K.H., Curtis K.D., Malfatti M.A., Turesky R.J., Garner R.C., Felton J.S., Lang N.P. Macromolecular adduct formation and metabolism of heterocyclic amines in humans and rodents at low doses. Cancer Lett. 1999, 143:149-155.
7. Turteltaub K.W., Dingley K.H. Application of accelerated mass spectrometry (AMS) in DNA adduct quantification and identification. Toxicol. Lett. 1998, 102-103:435-439.
8. Dingley K.H., Freeman S.P., Nelson D.O., Garner R.C., Turteltaub K.W. Covalent binding of 2-amino-3, 8-dimethylimidazo[4, 5-f]quinoxaline to albumin and hemoglobin at environmentally relevant doses. Comparison of human subjects and F344 rats. Drug Metab. Dispos. 1998, 26:825-828.
9. Dingley K.H., Ubick E.A., Vogel J.S., Haack K.W. DNA isolation and sample preparation for quantification of adduct levels by accelerator mass spectrometry. Meth. Mol. Biol. 2005, 291:21-27.
10. Mauthe R.J., Dingley K.H., Leveson S.H., Freeman S.P., Turesky R.J., Garner R.C., Turteltaub K.W. Comparison of DNA-adduct and tissue-available dose levels of MeIQx in human and rodent colon following administration of a very low dose. Int. J. Cancer 1999, 80:539-545.
11. Cupid B.C., Lightfoot T.J., Russell D., Gant S.J., Turner P.C., Dingley K.H., Curtis K.D., Leveson S.H., Turteltaub K.W., Garner R.C. The formation of AFB(1)-macromolecular adducts in rats and humans at dietary levels of exposure. Food Chem. Toxicol. 2004, 42:559-569.
12. Gilman S., Gee S., Hammock B., Vogel J., Haack K., Buchholz B., Freeman S., Wester R., Hui X., Maibach H. Analytical performance of accelerator mass spectrometry and liquid scintillation counting for detection of 14C-labeled atrazine metabolites in human urine. Anal. Chem. 1998, 70:3463-3469.
13. Buchholz B.A., Fultz E., Haack K.W., Vogel J.S., Gilman S.D., Gee S.J., Hammock B.D., Hui X., Wester R.C., Maibach H.I. HPLC-accelerator MS measurement of atrazine metabolites in human urine after dermal exposure. Anal. Chem. 1999, 71:3519-3525.
14. Clifford A.J., Arjomand A., Dueker S.R., Schneider P.D., Buchholz B.A., Vogel J.S. The dynamics of folic acid metabolism in an adult given a small tracer dose of 14C-folic acid. Adv. Exp. Med. Biol. 1998, 445:239-251.
15. Dueker S.R., Lin Y., Buchholz B.A., Schneider P.D., Lame M.W., Segall H.J., Vogel J.S., Clifford A.J. Long-term kinetic study of beta-carotene, using accelerator mass spectrometry in an adult volunteer. J. Lipid Res. 2000, 41:1790-1800.
16. Vuong L.T., Buchholz B.A., Lame M.W., Dueker S.R. Phytochemical research using accelerator mass spectrometry. Nutr. Rev. 2004, 62:375-388.
17. Kamen M.D. Tracers. Sci. Am. 1949, 180:30-40.
18. Goodman D.S., Blomstrand R., Werner B., Huang H.S., Shiratori T. The intestinal absorption and metabolism of vitamin A and beta-carotene in man. J. Clin. Invest. 1966, 45:1615-1623.
19. Sauberlich H.E., Hodges R.E., Wallace D.L., Kolder H., Canham J.E., Hood J., Raica N., Lowry L.K. Vitamin A metabolism and requirements in the human studied with the use of labeled retinol. Vitam. Horm. 1974, 32:251-275.
20. Code of Federal Regulations 10 part 20.10003.
21. Council Directive 97/43/Euratom: On health protection of individuals against the dangers of ionizing radiation in relation to medical exposure, and repealing Directive 84/466/Euratom, 1997.
22. Vogel J., Love A. Quantitating isotopic molecular labels with accelerator mass spectrometry. Meth. Enzymol. 2005, 402:402-422.
23. Vogel J. Accelerator mass spectrometry for quantitative in vivo tracing. Biotechniques 2005, 25-29. (Suppl).
24. Sandhu P., Vogel J.S., Rose M.J., Ubick E.A., Brunner J.E., Wallace M.A., Adelsberger J.K., Baker M.P., Henderson P.T., Pearson P.G., Baillie T.A. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metab. Dispos. 2004, 32:1254-1259.
25. Garner R. Less is more: the human microdosing concept. Drug Discov. Today 2005, 10:449-451.
26. European Medicines Agency, Position paper on non-clinical safety studies to support clinical trials with a single microdose, in, EMEA - Committee for Medicinal Products for Human Use (CHMP), London, 2004.
27. Food and Drug Administration, Guidance for industry, investigators, and reviewers-exploratory IND studies, in, US Department of Health and Human Services, FDA, CDER, Rockville, MD, 2006.
28. Balani S.K., Nagaraja N.V., Qian M.G., Costa A.O., Daniels J.S., Yang H., Shimoga P.R., Wu J.T., Gan L.S., Lee F.W., Miwa G.T. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry. Drug Metab. Dispos. 2006, 34:384-388.
29. Ings R. Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge. Bioanalysis 2009, 1:1293-1305.
30. Dueker S.R., Lohstroh P.N., Giacomo J.A., Vuong L.T., Keck B.D., Vogel J.S. Early human ADME using microdoses and microtracers: bioanalytical considerations. Bioanalysis 2010, 2:441-454.
31. Lappin G., Stevens L. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. Expert Opin. Drug Metab. Toxicol. 2008, 4:1021-1033.
32. EMEA ICH Topic M3 (R2): note for guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals 2009.
33. Sporty J., Lin S.J., Kato M., Ognibene T., Stewart B., Turteltaub K., Bench G. Quantitation of NAD+biosynthesis from the salvage pathway in Saccharomyces cerevisiae. Yeast 2009, 26:363-369.
34. Garner R. Accelerator mass spectrometry in pharmaceutical research and development-a new ultrasensitive analytical method for isotope measurement. Curr. Drug Metab. 2000, 1:205-213.
35. Garner R.C. The role of DNA adducts in chemical carcinogenesis. Mutat. Res. 1998, 402:67-75.
36. Hah S.S. Recent advances in biomedical applications of accelerator mass spectrometry. J. Biomed. Sci. 2009, 16:54.
37. Arjomand A. Accelerator mass spectrometry-enabled studies: current status and future prospects. Bioanalysis 2010, 2:519-541.
38. Lappin G., Garner R.C. Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry. Anal. Bioanal. Chem. 2004, 378:356-364.
39. Lappin G., Shishikura Y., Jochemsen R., Weaver R.J., Gesson C., Houston B., Oosterhuis B., Bjerrum O.J., Rowland M., Garner C. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur. J. Pharm. Sci. 2010, 40:125-131.
40. EUMAPP. European Union Microdose AMS Partnership Programme. (website). http://www.eumapp.com.
41. Olsen J.A., Lakshman M.R. Carotenoid conversions. Meth. Enzymol. 1990, 189:425-432.
42. Parker R.S. Absorption, metabolism, and transport of carotenoids. FASEB J. 1996, 10:542-551.
43. Burri B.J., Clifford A.J. Carotenoid and retinoid metabolism: insights from isotope studies. Arch. Biochem. Biophys. 2004, 430:110-119.
44. Lemke S.L., Dueker S.R., Follett J.R., Lin Y., Carkeet C., Buchholz B.A., Vogel J.S., Clifford A.J. Absorption and retinol equivalence of beta-carotene in humans is influenced by dietary vitamin A intake. J. Lipid Res. 2003, 44:1591-1600.
45. Porter C.J., Charman W.N. Lipid-based formulations for oral administration: opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs. J. Recept. Signal Transduct. Res. 2001, 21:215-257.
46. Porter C.J., Trevaskis N.L., Charman W.N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. 2007, 6:231-248.
47. Wasan K.M. The role of lymphatic transport in enhancing oral protein and peptide drug delivery. Drug Dev. Ind. Pharm. 2002, 28:1047-1058.
48. Wasan K.M. Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems. Drug Dev. Ind. Pharm. 2001, 27:267-276.
49. Lappin G., Garner R.C. The utility of microdosing over the past 5years. Expert Opin. Drug Metab. Toxicol. 2008, 4:1499-1506.
50. Garner R.C., Lappin G. The phase 0 microdosing concept. Br. J. Clin. Pharmacol. 2006, 61:367-370.
51. Garner C. Human phase 0 microdosing studies-results of the CREAM trial. Sci. Link Jpn. 2006, 20:133-147.
52. Levy G., Mager D.E., Cheung W.K., Jusko W.J. Comparative pharmacokinetics of coumarin anticoagulants L: physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. J. Pharm. Sci. 2003, 92:985-994.
53. Kuwano K., Hashino A., Asaki T., Hamamoto T., Yamada T., Okubo K., Kuwabara K. 2-[4-[(5, 6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl) acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist pro-drug. J. Pharmacol. Exp. Ther. 2007, 322:1181-1188.
54. Shapiro S.D., Endicott S.K., Province M.A., Pierce J.A., Campbell E.J. Marked longevity of human lung parenchymal elastic fibers deduced from prevalence of D-aspartate and nuclear weapons-related radiocarbon. J. Clin. Invest. 1991, 87:1828-1834.
55. Bhardwaj R.D., Curtis M.A., Spalding K.L., Buchholz B.A., Fink D., Bjork-Eriksson T., Nordborg C., Gage F.H., Druid H., Eriksson P.S., Frisen J. Neocortical neurogenesis in humans is restricted to development. Proc. Natl Acad. Sci. USA 2006, 103:12564-12568.
56. Perl S., Kushner J.A., Buchholz B.A., Meeker A.K., Stein G.M., Hsieh M., Kirby M., Pechhold S., Liu E.H., Harlan D.M., Tisdale J.F. Significant human {beta}-cell turnover is limited to the first three decades of life as determined by in Vivo thymidine analog incorporation and radiocarbon dating. J. Clin. Endocrinol. Metab. 2010, 95:E234-9.
57. Spalding K.L., Arner E., Westermark P.O., Bernard S., Buchholz B.A., Bergmann O., Blomqvist L., Hoffstedt J., Naslund E., Britton T., Concha H., Hassan M., Ryden M., Frisen J., Arner P. Dynamics of fat cell turnover in humans. Nature 2008, 453:783-787.
58. Beaudin A.E., Stover P.J. Insights into metabolic mechanisms underlying folate-responsive neural tube defects: a minireview. Birth Defects Res. A Clin. Mol. Teratol. 2009, 85:274-284.
59. Buchholz B.A., Arjomand A., Dueker S.R., Schneider P.D., Clifford A.J., Vogel J.S. Intrinsic erythrocyte labeling and attomole pharmacokinetic tracing of 14C-labeled folic acid with accelerator mass spectrometry. Anal. Biochem. 1999, 269:348-352.
60. Vuong L., Ruckle J., Blood A., Reid M., Wasnich R., Synal H., Dueker S. Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine. J. Pharm. Sci. 2008, 97:2833-2843.
61. Garner R.C. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data. Bioanalysis 2010, 2:429-440.
62. Williams M.L., Vogel J.S., Ghadially R., Brown B.E., Elias P.M. Exogenous origin of n-alkanes in pathologic scale. Arch. Dermatol. 1992, 128:1065-1071.
63. Buchholz B.A., Pawley N.H., Vogel J.S., Mauthe R.J. Pyrethroid decrease in central nervous system from nerve agent pretreatment. J. Appl. Toxicol. 1997, 17:231-234.
64. Gilman S.D., Gee S.J., Hammock B.D., Vogel J.S., Haack K., Buchholz B.A., Freeman S.P., Wester R.C., Hui X., Maibach H.I. Analytical performance of accelerator mass spectrometry and liquid scintillation counting for detection of 14C-labeled atrazine metabolites in human urine. Anal. Chem. 1998, 70:3463-3469.
65. Rickert D., Dingley K., Ubick E., Dix K., Molina L. Determination of the tissue distribution and excretion by accelerator mass spectrometry of the nonadecapeptide 14C-Moli1901 in beagle dogs after intratracheal instillation. Chem.-Biol. Interact. 2005, 155:55-61.
66. Conroy S., Newman C., Gudka S. Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children. Ann. Oncol. 2003, 14:42-47.
67. Turner S., Longworth A., Nunn A.J., Choonara I. Unlicensed and off label drug use in paediatric wards: prospective study. BMJ 1998, 343-345.
68. Leide-Svegborn S., Stenstrom K., Olofsson M., Mattsson S., Nilsson L.E., Nosslin B., Pau K., Johansson L., Erlandsson B., Hellborg R., Skog G. Biokinetics and radiation doses for carbon-14 urea in adults and children undergoing the Helicobacter pylori breath test. Eur. J. Nucl. Med. 1999, 26:573-580.
69. Gunnarsson M., Leide-Svegborn S., Stenstrom K., Skog G., Nilsson L.E., Hellborg R., Mattsson S. No radiation protection reasons for restrictions on 14C urea breath tests in children. Br. J. Radiol. 2002, 75:982-986.
70. Aklamati E.K., Mulenga M., Dueker S.R., Buchholz B.A., Peerson J.M., Kafwembe E., Brown K.H., Haskell M.J. Accelerator mass spectrometry can be used to assess vitamin A metabolism quantitatively in boys in a community setting. J. Nutr. 2010, 140:1588-1594.
71. Vuong L., Lohstroh P., Blood A., Vasquez H., Vogel J.S. Applying 14C-AMS in neonatal research and care. Special Issue: 10th Intranational Symposium on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds. J. Labelled Comp. Radiopharm. 2009, 53:346-354.
72. Vogel J.S., Keating G.A., Buchholz B.A. Protein binding of isofluorophate in vivo after coexposure to multiple chemicals. Environ. Health Perspect. 2002, 110(Suppl 6):1031-1036.
73. Prendergast M.A., Terry A.V., Buccafusco J.J. Effects of chronic, low-level organophosphate exposure on delayed recall, discrimination, and spatial learning in monkeys and rats. Neurotoxicol. Teratol. 1998, 20:115-122.
74. Palmblad M., Buchholz B.A., Hillegonds D.J., Vogel J.S. Neuroscience and accelerator mass spectrometry. J. Mass Spectrom. 2005, 40:154-159.
75. Grauer E., Alkalai D., Kapon J., Cohen G., Raveh L. Stress does not enable pyridostigmine to inhibit brain cholinesterase after parenteral administration. Toxicol. Appl. Pharmacol. 2000, 164:301-304.
76. Dingley K.H., Ubick E.A., Chiarappa-Zucca M.L., Nowell S., Abel S., Ebeler S.E., Mitchell A.E., Burns S.A., Steinberg F.M., Clifford A.J. Effect of dietary constituents with chemopreventive potential on adduct formation of a low dose of the heterocyclic amines PhIP and IQ and phase II hepatic enzymes. Nutr. Cancer 2003, 46:212-221.
77. Shipp A., Lawrence G., Gentry R., McDonald T., Bartow H., Bounds J., Macdonald N., Clewell H., Allen B., Van Landingham C. Acrylamide: review of toxicity data and dose-response analyses for cancer and noncancer effects. Crit. Rev. Toxicol. 2006, 36:481-608.
78. Xie Q., Sun H., Liu Y., Ding X., Fu D., Liu K. Adduction of biomacromolecules with acrylamide (AA) in mice at environmental dose levels studied by accelerator mass spectrometry. Toxicol. Lett. 2006, 163:101-108.
79. Mucci L.A., Dickman P.W., Steineck G., Adami H.O., Augustsson K. Dietary acrylamide and cancer of the large bowel, kidney, and bladder: absence of an association in a population-based study in Sweden. Br. J. Cancer 2003, 88:84-89.
80. Xie Q., Liu Y., Sun H., Ding X., Fu D., Liu K., Du X., Jia G. Inhibition of acrylamide toxicity in mice by three dietary constituents. J. Agric. Food Chem. 2008, 56:6054-6060.
81. Lappin G., Rowland M., Garner R.C. The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin. Drug Metab. Toxicol. 2006, 2:419-427.
82. Sarapa N., Hsyu P.H., Lappin G., Garner R.C. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J. Clin. Pharmacol. 2005, 45:1198-1205.
83. Carkeet C., Dueker S.R., Lango J., Buchholz B.A., Miller J.W., Green R., Hammock B.D., Roth J.R., Anderson P.J. Human vitamin B12 absorption measurement by accelerator mass spectrometry using specifically labeled (14)C-cobalamin. Proc. Natl Acad. Sci. USA 2006, 103:5694-5699.
84. Henderson P.T., Pan C.X. Human microdosing for the prediction of patient response. Bioanalysis 2010, 2:373-376.
85. Hah S.S., Sumbad R.A., de Vere White R.W., Turteltaub K.W., Henderson P.T. Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations. Chem. Res. Toxicol. 2007, 20:1745-1751.
86. Hah S.S., Stivers K.M., de Vere White R.W., Henderson P.T. Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry. Chem. Res. Toxicol. 2006, 19:622-626.
87. Brown K., Dingley K.H., Turteltaub K.W. Accelerator mass spectrometry for biomedical research. Meth. Enzymol. 2005, 402:423-443.
88. Schulze-König T., Dueker S.R., Giacomo J., Suter M., Vogel J.S., Synal H.-A. BioMICADAS: compact next generation AMS system for pharmaceutical science. Nucl. Instrum. Meth. Phys. Res. B 2010, 268:891-894.
89. Suter M., Döbeli M., Grajcar M., Müller A., Stocker M., Sun G., Synal H.-A., Wacker L. Advances in particle identification in AMS at low energies. Nucl. Instrum. Meth. Phys. Res. B 2007, 259:165-172.
90. Synal H., Stocker M., Suter M. Micadas: a new compact radiocarbon AMS system. Nucl. Instrum. Meth. Phys. Res. B 2007, 259:7-13.
91. Ognibene T.J., Bench G., Vogel J.S., Peaslee G.F., Murov S. A high-throughput method for the conversion of CO2 obtained from biochemical samples to graphite in septa-sealed vials for quantification of 14C via accelerator mass spectrometry. Anal. Chem. 2003, 75:2192-2196.
92. Middleton R. A review of ion sources for accelerator mass spectrometry. Nucl. Instrum. Meth. Phys. Res. B 1984, 5:193-199.
93. Bronk Ramsey C., Hedges R.E.M. Hybrid ion sources: radiocarbon measurements from microgram to milligram. Nucl. Instrum. Meth. Phys. Res. B 1997, 123:539-545.
94. Prakash C., Shaffer C.L., Tremaine L.M., Liberman R.G., Skipper P.L., Flarakos J., Tannenbaum S.R. Application of liquid chromatography-accelerator mass spectrometry (LC-AMS) to evaluate the metabolic profiles of a drug candidate in human urine and plasma. Drug Metab. Lett. 2007, 1:226-231.
95. Liberman R.G., Tannenbaum S.R., Hughey B.J., Shefer R.E., Klinkowstein R.E., Prakash C., Harriman S.P., Skipper P.L. An interface for direct analysis of (14)c in nonvolatile samples by accelerator mass spectrometry. Anal. Chem. 2004, 76:328-334.
96. Flarakos J., Liberman R.G., Tannenbaum S.R., Skipper P.L. Integration of continuous-flow accelerator mass spectrometry with chromatography and mass-selective detection. Anal. Chem. 2008, 80:5079-5085.
97. Murnick D.E., Okil J.O. Use of the optogalvanic effect (OGE) for isotope ratio spectrometry of 13CO2 and 14CO2. Isot. Environ. Health Stud. 2005, 41:363-371.
98. Lambert D.M. Rationale and applications of lipids as pro-drug carriers. Eur. J. Pharm. Sci. 2000, 11(Suppl 2):S15-S27.
99. Hah S.S., Mundt J.M., Kim H.M., Sumbad R.A., Turteltaub K.W., Henderson P.T. Measurement of 7, 8-dihydro-8-oxo-2'-deoxyguanosine metabolism in MCF-7 cells at low concentrations using accelerator mass spectrometry. Proc. Natl Acad. Sci. USA 2007, 104:11203-11208.